Alex Thurman Sells 10,000 Shares of Glaukos (NYSE:GKOS) Stock

Glaukos Corporation (NYSE:GKOS) CFO Alex Thurman sold 10,000 shares of Glaukos stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $140.00, for a total value of $1,400,000.00. Following the transaction, the chief financial officer directly owned 43,681 shares of the company’s stock, valued at approximately $6,115,340. This represents a 18.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Glaukos Stock Performance

Shares of GKOS stock opened at $133.36 on Wednesday. The stock has a fifty day moving average price of $114.28 and a 200 day moving average price of $108.35. The stock has a market cap of $7.83 billion, a PE ratio of -40.66 and a beta of 0.94. Glaukos Corporation has a 1 year low of $73.16 and a 1 year high of $146.75. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.73 and a current ratio of 5.43.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.12. The firm had revenue of $150.57 million during the quarter, compared to analysts’ expectations of $137.00 million. Glaukos had a negative return on equity of 6.92% and a negative net margin of 34.34%.Glaukos’s revenue was up 41.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.22) earnings per share. Sell-side analysts forecast that Glaukos Corporation will post -0.58 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

GKOS has been the subject of several recent research reports. Stifel Nicolaus set a $170.00 price target on Glaukos in a research report on Thursday, April 30th. Wall Street Zen raised Glaukos from a “hold” rating to a “buy” rating in a research report on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Glaukos in a research report on Tuesday, April 21st. Needham & Company LLC raised their price target on Glaukos from $127.00 to $136.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Finally, William Blair raised Glaukos to a “strong-buy” rating in a research report on Friday, January 30th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Glaukos presently has an average rating of “Moderate Buy” and a consensus price target of $144.42.

Key Glaukos News

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Needham reiterated a Buy on Glaukos, reinforcing analyst support and underpinning upside expectations for the shares. Needham Remains a Buy on Glaukos (GKOS)
• Positive Sentiment: Media coverage highlights a shifting narrative as Glaukos gives updated guidance and signals a product ramp (sustained drug-delivery and MIGS growth), which supports upside to revenue trajectory if execution continues. How The Glaukos (GKOS) Narrative Is Shifting With New Guidance And Product Ramp Expectations
• Neutral Sentiment: Recent quarter: revenue beat consensus and EPS outperformed estimates on stronger sales, supporting the case for durable top-line growth even though profitability remains negative. Analysts’ price targets were raised by some firms; consensus remains a Moderate Buy. MarketBeat GKOS summary
• Neutral Sentiment: CFO Alex Thurman sold 10,000 shares under a pre-arranged Rule 10b5-1 plan, which reduces the signal of opportunistic timing but still reduces insider holdings. CFO 10b5-1 sale filing
• Negative Sentiment: COO Joseph Gilliam sold 19,573 shares (~21% reduction in his position), a large insider sale that can raise investor concern about insider confidence or portfolio rebalancing. Glaukos COO Joseph Gilliam Sells 19,573 Shares
• Negative Sentiment: Director Leana Wen sold 1,700 shares, a smaller but visible insider sale disclosed via SEC filing — another factor that can pressure near-term sentiment. Director Leana Wen Sells 1,700 Shares

Institutional Investors Weigh In On Glaukos

A number of hedge funds and other institutional investors have recently made changes to their positions in GKOS. AQR Capital Management LLC grew its position in shares of Glaukos by 2.6% in the first quarter. AQR Capital Management LLC now owns 7,788 shares of the medical instruments supplier’s stock valued at $766,000 after purchasing an additional 198 shares during the period. Jones Financial Companies Lllp grew its position in shares of Glaukos by 1,405.9% in the first quarter. Jones Financial Companies Lllp now owns 2,560 shares of the medical instruments supplier’s stock valued at $252,000 after purchasing an additional 2,390 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Glaukos by 41.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 229,994 shares of the medical instruments supplier’s stock valued at $22,636,000 after purchasing an additional 67,668 shares during the period. M&T Bank Corp purchased a new stake in shares of Glaukos in the second quarter valued at $203,000. Finally, Gamco Investors INC. ET AL grew its position in shares of Glaukos by 10.7% in the second quarter. Gamco Investors INC. ET AL now owns 8,001 shares of the medical instruments supplier’s stock valued at $826,000 after purchasing an additional 773 shares during the period. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.